Tachyon Announces Financing and Start of Study of First-in-Class KDM4 Inhibitor
01 Mar 2023 //
BUSINESSWIRE
Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101
01 Mar 2023 //
BUSINESSWIRE
01 Mar 2023 //
BUSINESSWIRE
01 Mar 2023 //
BUSINESSWIRE